Asset profile
UCB0022
Small molecule
Evidence outlook · lead readout
ATLANTIS (NCT06055985) · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
ATLANTIS (NCT06055985): The study randomly assigned 207 participants to two UCB0022 dose groups or placebo, with participants, care providers, investigators, and outcome assessors masked. Its primary clinical endpoint was change in average daily OFF time. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| UCB0022: this drug | Phase 2 | Small molecule | D1 receptor | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 | ||
| Parcopa | Approved | Small molecule | dopamine precursor | ||
| Pimavanserin (Nuplazid) | Approved | Small molecule | 5-HT2A/2C receptor, Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| Pramipexole (Sifrol/Mirapex) | Approved | Small molecule | Dopamine D2/D3 receptors | ||
| Pramipexole ER (Mirapex ER) | Approved | Small molecule | Dopamine D2 / D3 receptors | ||
| Rasagiline (Azilect) | Approved | Small molecule | MAO-B |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.